Driven by a surging pipeline, the MASH therapeutic landscape is radically transforming as more drugs reach clinical trials. While Madrigal's Rezdiffra marked a groundbreaking first approval, it also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback